Heron Therapeutics, Inc. (HRTX) financial statements (2021 and earlier)

Company profile

Business Address 4242 CAMPUS POINT COURT, SUITE 200
SAN DIEGO, CA 92121
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:391332172511317372
Cash and cash equivalents723214513757372
Short-term investments319 283856  
Other undisclosed cash, cash equivalents, and short-term investments03010(0)0  
Receivables4065422   
Inventory, net of allowances, customer advances and progress billings2539105  
Inventory2539105   
Other undisclosed current assets231144411
Total current assets:479447228621357473
Noncurrent Assets
Operating lease, right-of-use asset14
Property, plant and equipment201565333
Other noncurrent assets0000000
Total noncurrent assets:341565333
TOTAL ASSETS:513462234671387776
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5563452212106
Accounts payable317197331
Accrued liabilities3733176455
Employee-related liabilities15139853 
Debt2      
Due to related parties  25    
Deferred revenue and credits31   
Other undisclosed current liabilities40293116741
Total current liabilities:97921033920147
Noncurrent Liabilities
Long-term debt and lease obligation12      
Operating lease, liability12
Liabilities, other than long-term debt   50   
Due to related parties   50   
Total noncurrent liabilities:12  50   
Total liabilities:109921038920147
Stockholders' equity
Stockholders' equity attributable to parent404370131(21)1186369
Common stock1110000
Additional paid in capital1,5681,330914564531378308
Accumulated other comprehensive income (loss)0(0)(0)(0)(0)  
Accumulated deficit(1,165)(961)(783)(586)(413)(315)(239)
Total stockholders' equity:404370131(21)1186369
TOTAL LIABILITIES AND EQUITY:513462234671387776

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues14677311   
Revenue, net311   
Cost of revenue
(Cost of Goods and Services Sold)
(62)(28)(5)(0)   
Gross profit:8450261   
Operating expenses(295)(261)(225)(172)(97)(75)(54)
Other undisclosed operating income 2850   
Operating loss:(211)(184)(195)(171)(97)(75)(54)
Nonoperating income (expense)65(3)(2)(1)(2)0
Investment income, nonoperating761    
Debt instrument, convertible, beneficial conversion feature     00
Other nonoperating income (expense)02(0)00(1) 
Interest and debt expense(1)(3)(4)(3)(1)(1) 
Loss before gain (loss) on sale of properties:(206)(182)(201)(176)(99)(77)(54)
Other undisclosed net income     1 
Net loss:(206)(182)(201)(176)(99)(76)(54)
Other undisclosed net income (loss) attributable to parent13431 (1)
Net loss available to common stockholders, diluted:(205)(179)(197)(173)(98)(76)(55)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(206)(182)(201)(176)(99)(76)(54)
Other comprehensive loss      (55)
Comprehensive loss:(206)(182)(201)(176)(99)(76)(109)
Other undisclosed comprehensive income, net of tax, attributable to parent23431  
Comprehensive loss, net of tax, attributable to parent:(205)(179)(197)(173)(98)(76)(109)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: